International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set.
Saved in:
| Title: | International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set. |
|---|---|
| Authors: | Samuel R; NIHR Manchester Biomedical Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.; University of Leeds, Leeds Institute for Medical Research, St. James's University Hospital, Leeds, UK., Knight SR; Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK.; School of Health and Wellbeing, University of Glasgow, Glasgow, UK., Adams R; Centre for Trials Research, Cardiff University School of Medicine, Cardiff, UK., Das P; University of Texas MD Anderson Cancer Center, USA., Dorth J; Department of Radiation Oncology, University Hospitals Cleveland Medical Centre, Cleveland, USA., Finch D; NIHR Manchester Biomedical Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.; Colorectal and Peritoneal Oncology Centre, The Christie NHS FT, Manchester., Guren MG; Department of Oncology, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Hawkins MA; Department of Medical Physics and Biomedical Engineering, University College London, London, UK., Moug S; Department of Colorectal Surgery, Royal Alexandra Hospital, Paisley, UK., Rajdev L; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Sebag-Montefiore D; University of Leeds, Leeds Institute for Medical Research, St. James's University Hospital, Leeds, UK., Renehan AG; NIHR Manchester Biomedical Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.; Colorectal and Peritoneal Oncology Centre, The Christie NHS FT, Manchester., Fish R; NIHR Manchester Biomedical Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.; Colorectal and Peritoneal Oncology Centre, The Christie NHS FT, Manchester. |
| Corporate Authors: | plus the CORMAC-2 collaborators |
| Source: | EClinicalMedicine [EClinicalMedicine] 2024 Dec 05; Vol. 78, pp. 102939. Date of Electronic Publication: 2024 Dec 05 (Print Publication: 2024). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: The Lancet Country of Publication: England NLM ID: 101733727 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5370 (Electronic) Linking ISSN: 25895370 NLM ISO Abbreviation: EClinicalMedicine Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
